Prostate Cancer Management Algorithm (PCMA)

For metastatic castration-sensitive prostate cancer (mCSPC), treatment intensification with ADT plus either abiraterone/prednisone, apalutamide, enzalutamide, or docetaxel is the standard of care, with triplet therapy (ADT + docetaxel + darolutamide or abiraterone) recommended for fit patients with high-volume disease. 1

Risk Stratification Framework

Localized Disease Categories

Very Low Risk:

Life expectancy <20 years → Active surveillance 2
PSA <10 ng/mL, Gleason ≤6, <3 cores positive, <50% cancer per core, PSA density <0.15 3

Low Risk:

Life expectancy <10 years → Watchful waiting 4
Life expectancy ≥10 years → Active surveillance (strong recommendation) 4
Treatment options if needed: Radical prostatectomy (RP) or external beam radiation therapy (EBRT) or brachytherapy 3

Intermediate Risk (T2b-T2c, Gleason 7, or PSA 10-20 ng/mL):

Life expectancy <10 years → Active surveillance or observation 2
Life expectancy ≥10 years → RP with pelvic lymph node dissection (PLND) if nodal metastasis risk ≥2%, OR EBRT (76-78 Gy or moderate hypofractionation 60 Gy/20 fractions) + short-term ADT (4-6 months) 4, 2
Critical: Brachytherapy monotherapy is NOT recommended for intermediate-risk disease 2

High Risk (T3a, Gleason 8-10, or PSA >20 ng/mL):

Preferred: EBRT + long-term ADT (24-36 months) 2
Alternative: RP with PLND in selected patients without organ fixation 2
For very high-risk M0 disease (N1 or ≥2 risk factors): Add abiraterone/prednisone for 24 months to RT + ADT 1

Very High Risk (T3b-T4):

EBRT + ADT (2-3 years) ± abiraterone 2
RP with PLND only in highly selected patients without fixation 2

Node-Positive (cN1 M0) Disease

Standard of care: Prostate + whole-pelvic RT + ADT (3 years) + abiraterone (2 years) 4

This combination improved metastasis-free survival (82% vs 69% at 6 years) and overall survival (HR 0.60) 4
Docetaxel did NOT show similar benefit in this population 4

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

First-Line Treatment Algorithm

For fit patients with de novo mHSPC, especially high-volume disease (>3 bone metastases or visceral metastases):

Triplet therapy (preferred):

ADT + docetaxel + abiraterone/prednisone (ESMO-MCBS score: 4) 1
ADT + docetaxel + darolutamide (ESMO-MCBS score: 4) 1

Doublet therapy (alternative):

ADT + abiraterone/prednisone (ESMO-MCBS score: 4) 1, 5
ADT + apalutamide (ESMO-MCBS score: 4) 1, 5
ADT + enzalutamide (ESMO-MCBS score: 4) 1, 5

Important distinction: High-volume disease (≥4 bone metastases with ≥1 beyond vertebral bodies or visceral metastases) shows more pronounced benefit from docetaxel (HR 0.63) 5

For vulnerable patients who cannot tolerate intensification: ADT alone 1

Prostate-Directed Therapy in mHSPC

Low-volume disease: Consider adding radiotherapy to ADT + systemic therapy 5

PEACE-1 trial showed improved radiographic PFS with RT added to ADT + abiraterone 1

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Treatment Sequencing Algorithm

First-line (if not previously exposed):

Androgen receptor pathway inhibitor (ARAT): abiraterone, enzalutamide, apalutamide, or darolutamide 6

After progression on ARAT + docetaxel:

For PSMA-expressing disease without PSMA-negative lesions:

¹⁷⁷Lu-PSMA-617 (ESMO-MCBS score: 4) 1

For BRCA1/2 alterations:

Olaparib after ARAT failure (ESMO-MCBS score: 3) 1

For fit patients:

Cabazitaxel (ESMO-MCBS score: 3) 1

Biochemical Recurrence Management

PSA-only recurrence after definitive therapy:

Early vs. deferred ADT: No survival benefit demonstrated with early ADT (HR 0.75,95% CI 0.40-1.41), but adverse quality of life effects with early treatment 5

Recommendation: Defer ADT until development of symptoms, metastases on conventional imaging, or PSA doubling time <6 months 5

Salvage options:

Salvage RT for post-prostatectomy recurrence
Salvage RP for post-RT recurrence (highly selected patients only; high morbidity) 2

Critical Pitfalls to Avoid

Do NOT use neoadjuvant ADT before radical prostatectomy - strongly discouraged 2
Do NOT offer brachytherapy monotherapy for intermediate-risk disease - inferior outcomes 2
Do NOT use steroidal antiandrogens as monotherapy for metastatic disease 7
Do NOT delay biopsy when PSA progression, DRE changes, or MRI changes occur during active surveillance 4
Exclude patients with cribriform or intraductal histology from active surveillance 4

Monitoring Protocols

Active surveillance:

PSA every 3-6 months 2
DRE every 6-12 months 2
Repeat biopsy at least once every 3 years for 10 years 4
MRI before confirmatory biopsy if not done initially 4

Post-treatment:

PSA every 6-12 months for first 5 years, then annually 2

What is the prostate cancer management algorithm (PCMA) recommended by oncology guidelines?

Have a follow-up question?